HUMAN MATERIAL TRANSFER AGREEMENT FOR RESEARCH PURPOSEHuman Material Transfer Agreement • September 6th, 2023
This Human Material Transfer Agreement (the “Agreement”) is entered into and made effective as of latest date of signature below (the “Effective Date”) by and between:
HUMAN MATERIAL TRANSFER AGREEMENT FOR RESEARCH PURPOSEHuman Material Transfer Agreement • June 27th, 2018
This Human Material Transfer Agreement (the “Agreement”) is entered into and made effective as of latest date of signature below (the “Effective Date”) by and between:
Cancer Immune Monitoring and Analysis Centers - Cancer Immunologic Data Commons (CIMAC-CIDC) Human Material Transfer Agreement (HMTA) Version: February 27, 2019Human Material Transfer Agreement • March 18th, 2019
This Human Material Transfer Agreement (“Agreement”) will be effective on the date of last authorized signature below, (“Effective Date”). The purpose of this Agreement is to transfer NCI-sponsored clinical trial biospecimens and associated data from [Provider Name], hereinafter referred to as “Provider”, to Dana-Farber Cancer Institute, Inc., Leland Stanford Junior University, the University of Texas MD Anderson Cancer Center, and the Icahn School of Medicine at Mount Sinai (each a “CIMAC”); and Dana-Farber Cancer Institute, Inc. (the “CIDC”) who will receive the data related to the biospecimens, (jointly the “Recipients”). Each Recipient and the Provider is hereafter individually referred to as a “Party” and jointly as the “Parties”.
OUTGOING HUMAN MATERIAL TRANSFER AGREEMENTHuman Material Transfer Agreement • June 29th, 2012
This Human Material Transfer Agreement for the transfer of human biological materials (“Agreement”) is made and entered into as of , 201_ (the “Effective Date”), by and between The Chordoma Foundation having offices at 512 S. Mangum Street, 1st Floor, Durham, NC 27701 (“Recipient”), and [specify entity], with offices at
